Literature DB >> 6060721

Immunotherapy of cancer--experience with primary sarcoma in the rat.

P Alexander.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 6060721      PMCID: PMC1902054     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN: 0035-9157


× No keyword cloud information.
  6 in total

1.  AN IMMUNOLOGICAL METHOD OF INCREASING THE SENSITIVITY OF PRIMARY SARCOMAS TO LOCAL IRRADIATION WITH X RAYS.

Authors:  A HADDOW; P ALEXANDER
Journal:  Lancet       Date:  1964-02-29       Impact factor: 79.321

2.  AN ECOLOGY OF CHILDHOOD.

Authors:  J APLEY
Journal:  Lancet       Date:  1964-07-04       Impact factor: 79.321

3.  Effect of nucleic acids from immune lymphocytes on rat sarcomata.

Authors:  P Alexander; E J Delorme; L D Hamilton; J G Hall
Journal:  Nature       Date:  1967-02-11       Impact factor: 49.962

4.  The paediatrician and the termination of pregnancy.

Authors:  R W Smithells
Journal:  Lancet       Date:  1966-01-01       Impact factor: 79.321

5.  Evidence for an immunological reaction of the host directed against its own actively growing primary tumor.

Authors:  Z B Mikulska; C Smith; P Alexander
Journal:  J Natl Cancer Inst       Date:  1966-01       Impact factor: 13.506

6.  Treatment of a murine leukemia with spleen cells or sera from allogeneic mice immunized against the tumor.

Authors:  P Alexander; D I Connell; Z B Mikulska
Journal:  Cancer Res       Date:  1966-07       Impact factor: 12.701

  6 in total
  3 in total

1.  Immunological factors in cysts of the jaws.

Authors:  P A Toller
Journal:  Proc R Soc Med       Date:  1971-05

2.  Immunotherapy of cancer.

Authors: 
Journal:  Can Med Assoc J       Date:  1968-03-16       Impact factor: 8.262

3.  Toxicological response of the model fungus Saccharomyces cerevisiae to different concentrations of commercial graphene nanoplatelets.

Authors:  Maria Suarez-Diez; Santiago Porras; Felix Laguna-Teno; Peter J Schaap; Juan A Tamayo-Ramos
Journal:  Sci Rep       Date:  2020-02-24       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.